
A $492m memory bill caps cockpit launch upside: initiate at Hold, $83.87 target
We initiate coverage on Visteon at Hold with an $83.87 12-month target, implying a +1.9% price return. Visteon supplies digital instrument clusters, cabin displays, domain controllers and electric-vehicle electronics to more than 30 original equipment manufacturer (OEM) partners. After third-quarter warranty charges of about $77m and a 22% one-year drop, today's share price already reflects a mid-cycle profit margin just above 11%.
- Memory chip and printed circuit board (PCB) inflation of about $490m leaves nearly $50m unrecovered in 2027. At 90% cost pass-through, adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) sit nearly 7% below consensus, trimming value by about $1 per share.
- Cabin displays and cockpit domain controllers (CDCs) drive +8.5% growth over market (GoM) in 2027 despite a 1% dip in customer car output. Growth over market measures how much faster Visteon's sales grow than vehicle production at its customers, before currency and pricing. Displays and CDCs reached nearly 28% of third-quarter sales, supported by Chery's high-performance cockpit (HPC) ramp and fourth-quarter launches with Geely and SAIC Motor.
- Software reuse lifts mid-cycle EBITDA margin to 11.0%, slightly below what today's price implies and reducing value by nearly $2 per share. Reusing about three-quarters of CDC code alongside a best-cost footprint lowered engineering and selling, general and administrative (SG&A) costs from 2019 to 2025. Containing third-quarter warranty charges adds back about 60 cents per share.
What the market is missing. Consensus models near-full cost recovery without pass-through margin dilution. Billing chip inflation at zero profit lifts 2027 sales above the Street, yet leaves adjusted EBITDA nearly 7% lower and diluted earnings per share (EPS) almost a fifth lower.
Catalysts. February 2027 full-year results and cost-recovery guidance decide the call. Guiding to 98% recovery or $6bn of annual bookings adds more than $1 per share each. Planned Geely and SAIC Motor launches test cabin growth into mid-2027.
Valuation and target. Applying the peer-median 6.29x enterprise value (EV) to last twelve months (LTM) normalised EBITDA of about $333m yields our $80.23 base-case value. Discounted cash flow (DCF) at a 9.8% weighted average cost of capital (WACC) gives about $88 per share. Weighting our bull, base and bear cases rolls forward to our target.
Risks. Carmaker insourcing and Chinese rivals capping long-run cost recovery at 90% would cut about $8 per share. Mid-cycle margin reversion to the 10-year mean costs nearly $7 per share, while chip shortages remain a first-half 2027 risk.
| FY end Dec, $m | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Net sales | 3,866 | 3,768 | 3,824 | 4,375 | 4,626 |
| Growth y/y | −2.2% | −2.5% | +1.5% | +14.4% | +5.7% |
| Adjusted EBITDA | 474 | 492 | 386 | 462 | 537 |
| Margin | 12.3% | 13.1% | 10.1% | 10.6% | 11.6% |
| Net income (GAAP) | 296 | 201 | 133 | 189 | 237 |
| Diluted EPS ($) | 10.61 | 7.28 | 5.07 | 7.73 | 10.58 |
| Growth y/y | −46.8% | −31.4% | −30.3% | +52.5% | +36.8% |
| Free cash flow | 290 | 277 | 74 | 101 | 251 |
| At $82.27, 13 Nov | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| P/E (diluted) | 7.8x | 11.3x | 16.2x | 10.6x | 7.8x |
| EV / Adj. EBITDA | 4.5x | 4.4x | 5.5x | 4.6x | 4.0x |
| P/B | 1.8x | 1.4x | 1.4x | 1.2x | 1.1x |
| FCF yield | 12.6% | 12.2% | 3.4% | 5.1% | 13.6% |
| Dividend yield | 0.0% | 0.7% | 1.8% | 1.9% | 2.0% |
| ROE | 24.1% | 12.8% | 9.1% | 12.5% | 15.1% |
| Net debt / Adj. EBITDA | −0.6x | −1.0x | −0.6x | −0.3x | −0.2x |
| P/E at $83.87 target | 7.9x | 11.5x | 16.5x | 10.8x | 7.9x |
Source: Company filings; Penmark Research estimates. Restated FY24A generally accepted accounting principles (GAAP) profit reflects a fourth-quarter 2025 deferred tax asset method change. Multiples show price-to-earnings (P/E), price-to-book (P/B), free cash flow (FCF) yield and return on equity (ROE) on bridge EV.
Skewed 0.65x upside-to-downside around our $80.23 base value keeps us at Hold
Source: Signals; Yahoo Finance; Penmark Research estimates. Dashed fan lines show 12-month rolled scenario values from present values at right.
Assumes 98% next-year cost recovery and a 12.0% mid-cycle margin on stronger cabin demand. Valued at the 7.26x peer upper-quartile multiple.
Assumes 90% next-year recovery, full pass-through thereafter and an 11.0% mid-cycle margin. Valued at the peer-median multiple.
Assumes 75% next-year recovery, a 90% long-run cap and an extra warranty charge. Margin reverts to 10.3% at 4.84x.
| Income statement, $m | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Net sales | 3,866 | 3,768 | 3,824 | 4,375 | 4,626 |
| Adjusted EBITDA | 474 | 492 | 386 | 462 | 537 |
| Depreciation & amort. | (96) | (109) | (121) | (130) | (134) |
| SBC, restruct. & other | (79) | (62) | (77) | (65) | (63) |
| Operating income | 299 | 321 | 188 | 268 | 340 |
| Net interest & affiliates | (1) | 17 | 14 | 7 | 5 |
| Income tax & NCI | (2) | (137) | (69) | (86) | (108) |
| Net income (Visteon) | 296 | 201 | 133 | 189 | 237 |
| Cash flow, $m | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Net income (incl. NCI) | 306 | 213 | 139 | 198 | 248 |
| D&A and SBC | 137 | 154 | 168 | 184 | 192 |
| Working cap., warr. & oth. | (16) | 43 | (83) | (123) | (28) |
| Operating cash flow | 427 | 410 | 224 | 259 | 413 |
| Capital expenditure | (137) | (133) | (150) | (158) | (162) |
| Free cash flow | 290 | 277 | 74 | 101 | 251 |
| Adjusted free cash flow | 300 | 292 | 100 | 111 | 256 |
| Dividends & buybacks | (63) | (72) | (274) | (193) | (242) |
| Balance sheet, $m | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Cash & restricted cash | 626 | 773 | 549 | 436 | 421 |
| Trade working cap., net | 356 | 342 | 356 | 429 | 439 |
| PP&E and intangibles | 523 | 746 | 811 | 839 | 867 |
| Other non-curr. & curr. | 852 | 985 | 1,084 | 1,084 | 1,084 |
| Condensed assets | 2,357 | 2,846 | 2,800 | 2,788 | 2,811 |
| Total debt | 319 | 301 | 326 | 311 | 296 |
| Net cash | 307 | 472 | 223 | 125 | 125 |
| Shareholders' equity | 1,229 | 1,568 | 1,464 | 1,514 | 1,567 |
| Per share & KPIs | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Weighted dil. shares (m) | 27.9 | 27.6 | 26.2 | 24.4 | 22.4 |
| Adjusted EPS ($) | n/r | 7.74 | 5.93 | 8.04 | 10.74 |
| Diluted EPS, GAAP ($) | 10.61 | 7.28 | 5.07 | 7.73 | 10.58 |
| Dividend per share ($) | 0.00 | 0.55 | 1.50 | 1.56 | 1.62 |
| FCF per share ($) | 10.39 | 10.04 | 2.83 | 4.16 | 11.19 |
| Book value / basic sh ($) | 45.02 | 58.51 | 59.25 | 66.06 | 75.54 |
| Growth over market | +4.0% | +6.0% | +5.5% | +8.5% | +7.5% |
| Cost recovery rate | n/a | n/a | 86.0% | 90.0% | 95.0% |
Source: Company filings; Penmark Research estimates. Condensed assets net accounts payable inside trade working capital alongside property, plant and equipment (PP&E), while key performance indicators (KPIs) track cabin demand and recovery. Adjusted EBITDA excludes depreciation and amortisation (D&A), stock-based compensation (SBC), restructuring, tax, net interest, non-controlling interests (NCI) and affiliate income. Adjusted FCF adds back cash restructuring.
Unrecovered memory costs leave FY27E adjusted EBITDA 6.6% below consensus at $462.1m
| Growth & margins | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Growth y/y | |||||
| Net sales | −2.2% | −2.5% | +1.5% | +14.4% | +5.7% |
| Adjusted EBITDA | +9.2% | +3.8% | −21.5% | +19.7% | +16.3% |
| Operating income | +8.7% | +7.4% | −41.3% | +42.0% | +27.1% |
| Diluted EPS (GAAP) | −46.8% | −31.4% | −30.3% | +52.5% | +36.8% |
| Dividend per share | n/a | n/a | +172.7% | +4.0% | +4.0% |
| Margins & coverage | |||||
| Underlying EBITDA mgn | 12.3% | 13.1% | 12.9% | 13.0% | 13.3% |
| Adjusted EBITDA mgn | 12.3% | 13.1% | 10.1% | 10.6% | 11.6% |
| Operating (EBIT) margin | 7.7% | 8.5% | 4.9% | 6.1% | 7.4% |
| Free cash flow margin | 7.5% | 7.4% | 1.9% | 2.3% | 5.4% |
| Adj. EBITDA / net int. | n/m (net interest income) | 149.6x | 96.3x | ||
| Capex / net sales | 3.5% | 3.5% | 3.9% | 3.6% | 3.5% |
| Returns & valuation | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Returns & leverage | |||||
| ROE (ending equity) | 24.1% | 12.8% | 9.1% | 12.5% | 15.1% |
| ROA (cond. assets) | 12.6% | 7.1% | 4.8% | 6.8% | 8.4% |
| ROCE (after-tax / IC) | 21.5% | 19.6% | 10.2% | 13.0% | 16.0% |
| Net debt / equity | −25.0% | −30.1% | −15.2% | −8.3% | −8.0% |
| Net debt / Adj. EBITDA | −0.6x | −1.0x | −0.6x | −0.3x | −0.2x |
| Valuation at $82.27 actual price | |||||
| P/E (diluted GAAP) | 7.8x | 11.3x | 16.2x | 10.6x | 7.8x |
| EV / Adjusted EBITDA | 4.5x | 4.4x | 5.5x | 4.6x | 4.0x |
| P/B (basic) | 1.8x | 1.4x | 1.4x | 1.2x | 1.1x |
| FCF yield | 12.6% | 12.2% | 3.4% | 5.1% | 13.6% |
| Dividend yield | 0.0% | 0.7% | 1.8% | 1.9% | 2.0% |
| P/E at $83.87 target | 7.9x | 11.5x | 16.5x | 10.8x | 7.9x |
Source: Company filings; Penmark Research estimates. Ratios cover earnings before interest and taxes (EBIT), return on assets (ROA) and return on capital employed (ROCE) over invested capital (IC). Net interest income turns to net expense in FY27E as surplus cash funds buybacks.
| Penmark vs consensus | 4Q26E | FY26E | FY27E | FY28E |
|---|---|---|---|---|
| Net sales ($m) | ||||
| Penmark estimate | 940 | 3,824 | 4,375 | 4,626 |
| Consensus / guide | 942 | 3,826 | 4,273 | 4,400* |
| Prior-year period | 948 | 3,768 | 3,824 | 4,375 |
| Diff. vs consensus / plan | −0.2% | −0.1% | +2.4% | +5.1%* |
| Growth y/y (Penmark) | −0.8% | +1.5% | +14.4% | +5.7% |
| Adjusted EBITDA ($m) & EPS ($) | ||||
| Penmark Adj. EBITDA ($m) | 120.0 | 386.0 | 462.1 | 537.3 |
| Consensus / plan | 135.7 | 401.7 | 494.8 | 590.0* |
| Diff. vs consensus / plan | −11.6% | −3.9% | −6.6% | −8.9%* |
| Penmark Diluted EPS ($) | 1.90 | 5.07 | 7.73 | 10.58 |
| Consensus EPS ($) | 2.18 | 5.35 | 9.57 | n/d |
| Diff. vs consensus EPS | −12.8% | −5.2% | −19.2% | n/d |
| EPS growth y/y (Penmark) | −29.1% | −30.3% | +52.5% | +36.8% |
Source: Consensus snapshot (MarketScreener and S&P Capital IQ, 11 estimates, 23 Oct 2026); Penmark Research estimates. Fourth-quarter consensus is implied from full-year less nine-month actuals; *FY28E comparator is the Investor Day plan.
| LTM / 3Q26, 13 Nov | VC | Peers | Diff. |
|---|---|---|---|
| Valuation multiples | |||
| EV / norm. trailing EBITDA | 6.44x | 6.29x | +2.5% |
| Forward P/E (FY27E Street)* | 8.60x | n/d | n/d |
| EV / LTM sales | 0.52x | 0.93x | −44.6% |
| Price / book (3Q26) | 1.44x | 1.59x | −9.4% |
| Margins, returns & growth | |||
| 3Q26 revenue growth (y/y) | +5.8% | +0.4% | +5.4pp |
| LTM EBITDA margin (rep.) | 7.8% | 12.8% | −5.1pp |
| LTM EBITDA mgn (ex-warr.) | 9.8% | 12.8% | −3.1pp |
| LTM ROIC | 11.4% | 15.4% | −4.0pp |
| Trailing ROE | 10.9% | 12.7% | −1.8pp |
Source: Signals; Yahoo Finance; Penmark Research estimates (five-peer median: Gentex, Autoliv, Lear, PHINIA, Adient). Table shows return on invested capital (ROIC) and normalised EV on trailing EBITDA; *peer forward consensus is not in dataset.
Why a 4.6x forward headline multiple reconciles to Hold: Peer multiples are measured after stock-based compensation and normal restructuring, so we deduct about $77m of both from mid-cycle earnings. That puts Visteon at 6.44x normalised trailing EBITDA, slightly above the peer median and right in line with today's share price and our target.
February 2027 recovery guidance decides whether Visteon re-rates from 6.44x normalised EBITDA
- Feb 2027Results, chief financial officer (CFO) handoff and recovery guide: we model 90% cost pass-through, while 98% adds over $1 per share.
- Feb 2027Annual bookings and warranty filing: reaching $6bn of awards adds about $1.60 per share, while the annual filing tests warranty containment.
- 1H 2027China cockpit and dynamic random-access memory (DRAM) supply: Geely and SAIC Motor ramps test cabin growth worth nearly $1 per share on forward earnings.
- FY27–Feb 28Underlying margin durability: quarterly results test whether underlying margin holds near 13% and supports an 11% mid-cycle floor.
Source: Q3 FY26 call; Penmark Research estimates.
- Chinese rivals and carmaker insourcing. Long-run cost recovery stays capped at 90% from 2029 onward. Prob. 25%; −$8.33/sh.
- Margin reversion to cycle average. Cost savings fade back to the 10.3% historical average. Prob. 35%; −$6.72/sh.
- First-half 2027 chip shortages and pushback. Customer car output drops 4% or recovery slows to 75%. Prob. 30–35%; up to −$2.76/sh.
- Upside risk: durable 12% margin or lower cost of equity. Either shift lifts our target above $93 per share into Buy territory. Prob. 30%.
Source: Penmark Research estimates.
Source: MarketScreener consensus (23 Oct 2026); Penmark Research estimates (13.0% underlying margin less fifth-generation double data rate (DDR5) and PCB leakage).
Valuation anchor: The dashed line marks the five-peer trailing median (Gentex). Our bear and bull cases use the lower-quartile (Lear) and upper-quartile (PHINIA) peer multiples.
Source: Signals; Penmark Research estimates at 13 Nov 2026 (BorgWarner, Aptiv and Magna excluded).
| Indicator | Penmark base | Thesis confirmed (Hold) | Upgrade / Buy trigger | Downgrade / Sell trigger |
|---|---|---|---|---|
| FY27 cost recovery | 90% ($49.2m leak) | 88%–93% in Feb 2027 guide | ≥98% recovery & ≥$510m EBITDA | ≤75% recovery; OEM pushback |
| Growth over market | +8.5% FY27E | +7.5% to +9.0%; China HPC live | ≥+9.5% with $6.0bn+ FY26 wins | ≤+6.0%; China HPC slip |
| Underlying EBITDA mgn | 13.0% FY27E (11.0% mid) | 12.7%–13.2% ex-pass-through | ≥13.5% sustained (12.0% mid-cycle) | ≤11.5% (reversion toward 10.3%) |
| Warranty & CFO transition | $0m extra FY27E | Q3 $77m settled within accrual | Early permanent CFO; clean 10-K | $20m+ additional warranty charge |
Source: Penmark Research estimates.
Today's share price already discounts an 11.2% mid-cycle margin, leaving +1.9% upside
Quarterly adjusted EBITDA margin moved with quarter-end share prices over the past eight quarters (correlation +0.62, directional only on eight observations). After the third-quarter warranty reset, today's share price already reflects near-mid-cycle profitability, leaving cost pass-through and discount rates as the main swing factors.
Lead driver: Excluding about $77m of warranty charges, third-quarter margin held near 13%, showing core operations remained intact.
Source: Company filings; Yahoo Finance; Penmark Research estimates.
Estimate gap: Recovering 90% of the chip bill leaves nearly $50m unrecovered, putting profit 11% below management's plan.
Source: Filings (A); Investor Day; Penmark Research estimates & consensus (E).
Price versus value: Market expectations for slightly higher margins and full pass-through outweigh our relief on warranty costs.
Source: Penmark Research estimates.
Valuation context: Enterprise value now sits inside the lower historical multiple band, matching peers on normalised earnings.
Source: Signals; Yahoo Finance; Penmark Research estimates, actual quarterly LTM adjusted EBITDA (2Q22–3Q26).
Source: Penmark Research estimates.
Street lag: Consensus targets average about $112 despite recent cuts, well above our target and base-case value.
Source: MarketBeat consensus snapshot, 15 Nov 2026; Penmark Research estimates.
Three priced debates net to −$2.04 per share against today's $82.27 price
Today's share price implies an 11.2% mid-cycle margin, full long-run cost recovery and a lingering warranty discount. Replacing those three market views with ours reduces value by about $2 per share to our base-case value. Cockpit growth over market has zero weight in that trailing multiple gap and instead drives our multi-year cash flow forecast.
| Key debate | Market / Street view | Penmark view | Evidence & $/sh impact | What changes view | Resolves |
|---|---|---|---|---|---|
| Mid-cycle underlying margin | Price implies 11.22% ($81.89/sh); Investor Day targets 14.1% by FY29. | 11.0% mid-cycle (13.0% FY27E normalising over the cycle). | Platform reuse (~75% of CDC code) and a best-cost footprint lowered engineering and SG&A costs from FY19–25. −$1.67/sh | Sustained ≥13.5% ex-recovery (+$9.25) or fade to 10.3% (−$6.72). | FY27–Feb 28 |
| FY27E memory & PCB recovery | Street $494.8m adj. EBITDA (~near-100% pass-through; $81.20/sh). | 90% FY27E recovery on $491.6m bill ($49.2m leak; $462.1m EBITDA). | FY26 recovery ran ~86%; after the 2022 cost wave, margins rebuilt from 9.3% to 11.0% by FY23. −$0.97/sh | Feb 2027 guide ≥98% (+$1.17/sh) or ≤75% (−$2.19/sh). | Feb 2027 |
| Warranty containment | Post-Q3 sell-off prices ~$20m further warranty charge ($79.64/sh). | $0m extra in FY27E base; $20m tail only in 25% bear case. | Third-quarter filing calls $77m the best estimate for two warranty matters; extra $20m is not probable. +$0.59/sh | Extra warranty charge ≥$20m in FY26 10-K (−$0.59/sh). | Feb 2027 |
| Cockpit GoM vs China & OEM mix | Bulls extrapolate +10% Q3 GoM to $4.8bn FY29; bears fear China insourcing. | +8.5% FY27E GoM on −1.0% output ($4,375m sales, +2.4% vs Street). | 65 nine-month launches, $3.9bn wins and China HPC ramps. $0.00/sh in trailing gap (~$0.92/sh FY27E; $0.68/sh DCF per 1pt). | FY26 wins ≥$6.0bn (+$1.60) or 90% long-run recovery cap (−$8.33). | 4Q26–Jul 27 |
Source: Q3 FY26 Form 10-Q and earnings call; Investor Day 2026; Penmark Research estimates.
Source: Penmark Research estimates. Three priced debates sum to −$2.04/sh.
Where each debate is tested in our thesis
- Memory and board cost recovery: Tests fourth-generation double data rate (DDR4) end-of-life and board inflation against 90% pass-through and Street profit estimates.
- Cockpit growth and China launches: Quantifies +8.5% 2027 growth over market from displays, domain controllers and China ramps despite lower car output.
- Mid-cycle margin and warranty risk: Weighs software reuse supporting an 11.0% mid-cycle margin against third-quarter warranty containment.
Source: Form 8-K (27 Oct 2026); Q3 FY26 call; Penmark Research estimates.
Reuse 75% of the cockpit code, then haggle over a $490m memory bill
Visteon builds the digital screens and cabin computers inside cars for more than 30 OEM partners, turning a 2000 Ford spin-off into a nearly $3.8bn electronics specialist. Yet because carmaker orders carry no volume floor and chipmakers are retiring older memory, next year's profit hinges on passing through that cost wave.
The scene
Last quarter, Visteon launched 21 new cabin products across 14 carmakers even as its customers built 5% fewer vehicles. Operating across 17 countries, Visteon designs digital instrument clusters, curved displays and SmartCore cabin computers for Ford, General Motors, Volkswagen, Geely and more than two dozen peers.
What it actually does
Old dashboards wired separate gauges and radios to dozens of small chips. Visteon merges them onto single glass panels run by one domain controller that handles safety gauges alongside entertainment and voice software. That shift lifts content per vehicle (CPV) from about $125 on basic clusters up to $1,000 on full-width displays.
How the money comes in
Carmakers pay per unit shipped under purchase orders with zero volume guarantees, and we assume a 1.5% annual drag from price-downs and foreign exchange (FX). Instrument clusters generate nearly half of sales, while displays, infotainment and domain controllers contribute almost another two-fifths. Every dollar of 2025 revenue left about 14 cents of gross profit and just over 7 cents of free cash flow.
Where the story turns
After shedding legacy climate and interiors, chief executive officer (CEO) Sachin Lawande rebuilt Visteon around reusable software, more than doubling adjusted EBITDA from 2019 to 2025. Late 2026 then brought two jolts. Third-quarter results carried about $77m of warranty charges, and memory makers began ending automotive DDR4 supply just as circuit boards tightened.
Why it works, and why it might not
Once certified inside a car platform, switching a cabin supplier mid-programme rarely pays, keeping launches compounding across 65 programmes in the first nine months of 2026. Pass-through friction and Chinese rivals are the catch: we assume 90% memory recovery next year and an 11.0% mid-cycle margin, leaving the shares fairly priced ahead of February 2027 guidance.
Exhibit 26: One cabin programme from award to cash, keeping 7.4 cents of FCF per dollar of FY25A sales. Source: FY25 Form 10-K; Investor Day 2026; Signals; Penmark Research estimates.
Europe and North America generate 64% of Visteon's $3,768m annual sales
Visteon operates as a single Electronics segment across 17 countries, turning carmaker purchase orders into cabin hardware and software revenue. Net working capital (NWC) sits near 9% of sales, and 97% of manufacturing staff work in best-cost countries. That asset-light setup converts more than half of adjusted EBITDA into GAAP free cash flow.
Regional revenue in the annual report nets $150m of inter-region eliminations against Asia and South America. China sales split roughly three-fifths domestic programmes and two-fifths export builds.
Source: FY25 Form 10-K, Note 20; Penmark Research estimates.
Source: FY25 Form 10-K; Signals; Penmark Research estimates. Cost of sales includes $220m of net engineering expense after customer reimbursements.
Fixed versus variable cost structure. Chips, display panels and circuit boards account for roughly 86% of revenue inside variable cost of sales. Reusing about three-quarters of CDC software alongside a best-cost plant footprint lowered engineering and overhead costs. Adjusted SG&A fell from 6.7% to 4.6% of sales since 2019, while adjusted gross margin rose more than three points.
Cash versus accounting profit. Last year, nearly $500m of adjusted EBITDA converted into $410m of operating cash flow and $277m of free cash flow. Capital spending absorbed 3.5% of sales. Across this year and next, third-quarter warranty payouts and pricier chip inventory temporarily compress annual free cash flow toward $75m to $100m.
Customer cost recoveries and cabin launches lift FY27E sales 14.4% to $4,375m
Visteon's revenue splits into underlying cabin growth, net of price-downs and foreign exchange (FX), plus zero-margin component pass-throughs. Highlighted boxes in the revenue tree mark the two assumptions behind our gap to consensus: +8.5% growth over market and 90% recovery on next year's memory bill.
Source: Penmark Research estimates. Underlying FY26E base = $3,717m ($3,824m less $107m FY26E recoveries).
Nine-month display revenue rose 30% year on year to $476m, overtaking infotainment on multi-screen cabin launches.
Source: Q3 FY26 Form 10-Q; Penmark Research estimates. Clusters = $1,367m; other includes head-up display (HUD).
Expanding business with Toyota, Honda, Geely, Chery, SAIC Motor, Tata and Mahindra spreads customer exposure across more than 30 OEM partners.
Source: FY25 Form 10-K, Item 1; Investor Day.
Purchase-order pricing and volume exposure. Carmaker awards run on purchase orders without minimum volume floors and often allow cancellation for convenience. We assume a 1.5% annual drag from net price-downs and currency. When Ford or General Motors trims electric schedules, Visteon feels immediate volume pressure, and chip surcharges must be agreed customer by customer.
Geographic and supplier concentration. Plant shipments are anchored in the United States and Portugal, which together generate roughly half of gross regional sales alongside China, India and Japan. On the supply side, concentrated automotive DRAM and high-layer circuit-board capacity drive next year's memory cost wave.
Cockpit consolidation lifts content per vehicle from $125 up to $1,000
Cabin electronics revenue grows through rising content per car rather than global vehicle output. Even as customer output fell 5% in the first nine months of 2026, larger liquid-crystal display (LCD) and organic light-emitting diode (OLED) screens kept Visteon outgrowing its markets.
Source: FY25 Form 10-K; Q2 & Q3 FY26 calls; Investor Day.
Merging clusters and infotainment onto one controller doubles compute value, while curved OLED and LCD panels reach $1,000.
Source: Visteon Investor Day presentation (25 Jun 2026).
Adjacent two-wheeler and commercial runway. Management sizes the two-wheeler market outside China at about 51m annual units. Connected thin-film transistor (TFT) screens are driving an 8.5% compound annual growth rate (CAGR) in India and Southeast Asia through 2029.
Customer car output is guided down about 6% in the fourth quarter. We then model a 1% dip in 2027 before modest growth resumes.
Source: Signals KPIs (1Q25–3Q26); Q3 FY26 deck.
Profit pool squeeze from memory and boards. Upstream chipmakers such as Micron, Samsung and SK Hynix are shifting wafer capacity toward artificial intelligence (AI) data-centre high-bandwidth memory (HBM) and fifth-generation double data rate (DDR5) chips, ending legacy automotive DDR4 production. Alongside tight multi-layer circuit boards, that shift creates roughly $490m of 2027 cost inflation and tests pass-through discipline.
Substitution and architecture shifts. Carmaker software insourcing and rapid iteration by domestic Chinese suppliers both cap long-run pricing power. Even so, management noted on the third-quarter call that memory redesign complexity is slowing new awards and prompting several Western carmakers to favour turnkey supplier platforms over full insourcing.
Focused cockpit software helped Visteon grow third-quarter sales +5.8%, outpacing Western peers
Visteon competes as a focused cabin specialist against large diversified suppliers such as Aptiv, Bosch and Denso alongside fast-moving Chinese rivals led by Desay SV. That focus delivered nearly 6% third-quarter revenue growth, though smaller scale limits pricing leverage against carmakers.
Source: Yahoo Finance snapshot (13 Nov 2026); Signals. Ex-warranty VC LTM margin is 9.8% (FY25A adj. 13.1%).
Source: Penmark Research assessment from FY25 10-K, Investor Day and Q2–Q3 calls.
Where Visteon wins and cedes ground: In-house optical bonding and reusable software win global carmaker quotes. Faster domestic rivals keep China at roughly a tenth to a seventh of Visteon's sales mix depending on export attribution.
| Product line (FY25A) | Primary named 10-K competitors | Substitutes & structural threat | Visteon position & moat durability |
|---|---|---|---|
| Instrument clusters ($1,747m, 46%) | Denso, Continental, Bosch, Marelli, Nippon Seiki, Valeo | Consolidation into a single central screen | Mature cash generator; multi-year vehicle certification plus two-wheeler growth in India and Southeast Asia. |
| Displays & infotainment ($1,008m, 27%) | Harman (Samsung), LG Electronics, Panasonic, Alpine, BOE | Commodity panel assembly and smartphone projection | Display sales rose 30% in 9M26 on in-house optical bonding, backlighting and curved glass. |
| Cockpit CDC & AI ($428m, 11%) | Aptiv, Bosch, Harman, Desay SV, Hyundai Mobis | Carmaker central compute and Chinese system-on-chip (SoC) kits | Roughly 75% SmartCore code reuse; Chery ramp and fourth-quarter Geely and SAIC Motor launches test China traction. |
| Body & electric power ($420m, 11%) | BorgWarner, Valeo, Denso, LG, Hitachi Astemo | Delayed Western electric launches and in-house battery packs | Wireless and wired battery management system (BMS) hardware; softened by slower Western electric builds. |
Source: FY25 Form 10-K, Item 1 & Note 20; Q3 FY26 10-Q & call; Investor Day.
Visteon turned $1,410m of operating cash flow (OCF) since FY21 into $463m of buybacks
Since taking over in June 2015, Sachin Lawande has reshaped Visteon into a net-cash cockpit specialist, more than doubling adjusted EBITDA between 2021 and 2025. Board oversight is conventional, with an independent chair and seven independent directors. However, chief financial officer (CFO) Jerome Rouquet departs on 30 November 2026 just ahead of 2027 pass-through talks.
| Executive / governance item | Role & status | Pay & proxy ownership (Apr 15, 2026) | Alignment & assessment |
|---|---|---|---|
| Sachin S. Lawande | President, CEO & Director (since Jun 2015) | $12.88m FY25 target pay; 421,630 shares (1.6%) + 85,142 stock units | Led cabin software pivot; roughly 76% of executive pay is at risk on EBITDA, FCF, ROIC and shareholder return. |
| Jerome J. Rouquet → Colleen E. Myers | Outgoing CFO (leaves 30 Nov 26) → Interim CFO (Chief Acct. Officer) | Rouquet $2.96m FY25 target; Myers base lifted to $330k + $25k monthly stipend | Filing confirms no accounting or policy dispute; interim handover during warranty review and 2027 guide warrants watching. |
| Other executives & insider group | Pynnonen (Legal), Vallance (Commercial), Trecker (HR) | $1.60m–$1.90m target pay; all officers/directors held 532,254 sh (2.0%) + 239,339 units | Pre-scheduled Rule 10b5-1 sales in June 2026 (8,000 shares combined at $116.50–$120.00) executed near highs. |
| Board & pay metrics | 7 of 8 nominees independent; separate Chair since 2012 | Annual bonus: 40% Adj. EBITDA, 30% Adj. FCF, 30% goals. Long-term units: 50% ROIC, 50% relative return | Roughly 89% 2025 Say-on-Pay support; single-class common stock; independent audit committee oversight. |
Source: 2026 proxy statement (DEF 14A filed 28 Apr 2026, latest proxy ownership as of 15 Apr 2026); Form 8-K (27 Oct 2026); Signals Form 4s.
Source: Signals cash flow statements; Investor Day; Penmark Research estimates (includes mergers and acquisitions (M&A) and FY21–9M FY26 buybacks).
Source: Q3 FY26 release; Investor Day 2026; Penmark Research estimates (Adjusted FCF basis; prior dot = June $475m EBITDA objective).
Capital return versus dilution. Share buybacks since 2021 have more than offset annual stock-based pay, shrinking diluted shares by roughly 3m since 2023. Management's multi-year plan targets about $1bn of adjusted free cash flow through 2029 alongside existing cash. Roughly 70% of that pool is earmarked for buybacks, with the rest split between dividends, debt and joint venture (JV) payouts.
Guidance track record. Four-year adjusted FCF of $842m beats the 2023 target of over $800m. However, it misses June 2026's outlook of more than $900m after third-quarter warranty charges forced an October guidance cut.
Margin resets sparked two-day drops of up to −12.8%, driving Visteon's stock moves
Across Visteon's last ten corporate events, the shares moved sharply whenever margin durability or cost pass-through shifted rather than on market beta. Broad S&P 500 moves explain only about 15% of weekly variance over five years, leaving more than two-fifths to company-specific news. Memory pass-through and cabin launches together drove nearly two-thirds of analyst questions on 2026 earnings calls.
Investor Day lesson: On 25 June 2026, management outlined multi-year sales and margin ambitions, yet the shares fell nearly 13% over two days. Investors discounted distant margin goals ahead of DDR5 cost inflation and Western electric-vehicle delays.
Source: Penmark analysis using Yahoo Finance daily closes around ten Visteon events (Feb 2025–Oct 2026).
Mid-cycle underlying margin
Confirmed by three of four tests. Shares fell nearly 13% on both Investor Day and fourth-quarter margin guidance. Our 11% mid-cycle margin sits nearly $1.70 per share below market-implied expectations.Memory and PCB cost recovery
Confirmed by three of four tests. Pass-through drove over a third of 2026 call questions. Our 90% recovery base sits about $1 per share below near-full Street pass-through.Cockpit growth over market and China launches
Confirmed by two of four tests. Shares jumped nearly 14% over two days on first-quarter launch strength. Each point of 2027 growth over market adds almost $1 per share on forward earnings.Warranty containment and CFO transition
Confirmed by two of four tests. Shares fell 10% on third-quarter warranty charges and over 4% on the finance chief filing. Zero extra 2027 charges add about $0.60 per share against market fears.Multi-year return and beta context
Visteon fell about 22% over one year and a third over five years as multiples compressed despite EBITDA more than doubling. Five-year weekly regression beta of 0.86 sits below our tested discount-rate range. Using that lower beta would imply a Buy rating, underscoring our low Hold conviction.
Candidates tested and dropped
Four common narratives failed our tests. Regional plants naturally hedge currency translation. Share buybacks since 2021 also dwarf the quarterly dividend initiated in 2025, while tax swings and headline car sales failed to explain event-day moves.
Unrecovered memory and board costs of $49.2m trim value by −$0.97 per share
Source: Q3 FY26 call; Penmark Research estimates (FY26E–30E).
What the market believes
Published consensus models nearly $495m of 2027 adjusted EBITDA, embedding fuller cost pass-through than our base case. Pricing near-full recovery next year implies about $81 per share against our base-case value. Solving today's share price for long-run pass-through alone separately implies recovery slightly above 100%.
Independent evidence
Earnings call sizing: Management sized next year's memory and electronics inflation near $500m on the third-quarter call. They aim to protect profit dollars rather than percentage margins. Recovery track record: Pass-through ran near 86% in 2026. After the 2022 cost wave, margins rebuilt from roughly 9% to 11% within a year. Contract structure: Carmaker purchase orders carry no automatic commodity escalators. Visteon must negotiate customer surcharges or redesign boards for newer DDR5 memory with suppliers such as Micron.
| $m unless stated | FY26E | FY27E Penmark | FY27E Street | FY27E Plan | FY28E | FY29E |
|---|---|---|---|---|---|---|
| Underlying cockpit net sales | 3,717.1 | 3,932.9 | n/d | n/d | 4,206.0 | 4,498.2 |
| Gross component cost inflation | 124.3 | 491.6 | n/d | pre-shock | 441.6 | 404.8 |
| OEM pass-through recovery rate | 86.0% | 90.0% | n/d | n/a | 95.0% | 100.0% |
| Customer cost-recovery revenue (0% mgn) | 106.9 | 442.4 | n/d | n/a | 419.6 | 404.8 |
| Total net sales | 3,824.0 | 4,375.3 | 4,273.0 | 4,150.0 | 4,625.6 | 4,903.0 |
| Unrecovered component leakage | (17.4) | (49.2) | n/d | 0.0 | (22.1) | 0.0 |
| Adjusted EBITDA | 386.0 | 462.1 | 494.8 | 520.0 | 537.3 | 611.8 |
| Reported Adj. EBITDA margin (vs 13.0% underlying FY27E) | 10.1% | 10.6% | n/d | 12.5% | 11.6% | 12.5% |
Source: MarketScreener and MarketBeat consensus; Investor Day 2026; Penmark Research estimates. Guiding to near-full recovery next year adds over $1 per share, whereas 75% recovery costs more than $2. A permanent 90% recovery cap would cut value by over $8 per share.
Display and controller ramps drive +8.5% growth over market on −1.0% car output
Source: Q3 FY26 Form 10-Q & FY25 Form 10-K product-line tables.
Source: Signals quarterly KPIs (1Q26–3Q26).
What the market believes
Consensus models nearly $4.3bn of 2027 revenue, under-counting zero-margin cost recoveries while doubting China momentum. Bulls instead extrapolate recent launch growth straight toward management's $4.8bn sales ambition for 2029. That bullish view ignores award delays as carmakers redesign older memory boards.
Independent evidence
Quarterly launch cadence: Visteon launched 65 new products across the first nine months of 2026. Growth over market accelerated to 10% in the third quarter even as customer car builds fell 4% to 5%.
Product-line mix shift: Nine-month cabin display revenue jumped 30% year on year to nearly $480m. European sales also rose almost a fifth in the third quarter, offsetting softer battery-management demand on delayed Western electric models.
China ramps and bookings: Chery's high-performance controller is ramping in production, with Geely and SAIC Motor launches slated for the fourth quarter. Nine-month awards reached almost $4bn despite memory-related quote delays.
What it is worth
Our growth-over-market forecast lifts next year's underlying sales nearly 6% to about $3.9bn, or $4.4bn with cost recoveries. Each percentage point of 2027 growth over market is worth about $0.92 per share on next year's earnings, or roughly $0.68 in our DCF. Our primary trailing valuation does not move directly, while each point of customer car output shifts DCF value by about $0.74 per share.
Software reuse supports an 11.0% mid-cycle margin, trimming −$1.67 per share versus price
Source: Company filings (FY16A–25A); Penmark Research estimates (FY26E–35E).
What the market believes
Today's share price implies a mid-cycle margin just above 11%. It also prices roughly $20m of further warranty charges. Bulls point to management's 14% margin ambition for 2029, whereas bears expect reversion toward the 10% historical average.
Independent evidence
Reuse and footprint: Reusing about three-quarters of CDC software alongside a best-cost footprint lowered engineering and overhead costs. Overhead fell by two points of sales and gross margin rose over three points since 2019, helping lift EBITDA margin by more than five points across several drivers. Cycle record: Ten-year adjusted EBITDA margin averaged just over 10%, supporting mid-cycle normalisation down to 11% (customer price-downs are already in sales growth). Warranty filing: Management accrued $77m across two warranty matters, with up to $20m extra reasonably possible rather than probable.
| Margin & cost structure | FY19A | FY21A | FY23A | FY25A | FY27E | FY29E | FY35E |
|---|---|---|---|---|---|---|---|
| Net sales ($m) | 2,945 | 2,773 | 3,954 | 3,768 | 4,375 | 4,903 | 5,842 |
| Adjusted SG&A / net sales | 6.7% | 6.4% | 4.9% | 4.6% | n/m | n/m | n/m |
| Underlying EBITDA margin (ex-pass-through) | 7.9% | 8.2% | 11.0% | 13.1% | 13.0% | 13.6% | 11.0% |
| Reported Adjusted EBITDA margin | 7.9% | 8.2% | 11.0% | 13.1% | 10.6% | 12.5% | 10.1% |
Source: Investor Day 2026; Signals; Penmark Research estimates (SG&A is not forecast separately).
| Valuation lever | Market-implied | Penmark base | Gap vs price | Bull case | Bear case |
|---|---|---|---|---|---|
| Mid-cycle underlying EBITDA margin | 11.22% ($81.89) | 11.0% ($80.23) | −$1.67/sh | 12.0% (+$9.25/sh) | 10.3% (−$6.72/sh) |
| Incremental warranty accrual (pre-tax) | ~$20m ($79.64) | $0m ($80.23) | +$0.59/sh | $0m ($0.00/sh) | $20m (−$0.59/sh) |
Source: Penmark Research estimates.
Stock compensation of $45m and $77m of warranty charges require earnings normalisation
Five-year results paired genuine cabin software leverage with one-off tax, warranty and pass-through noise. Annual sales rose by more than a third since 2021 to nearly $3.8bn as adjusted EBITDA more than doubled. Company-defined adjusted EBITDA excludes non-cash SBC while absorbing exceptional third-quarter warranty charges. Our valuation deducts trailing SBC and normal restructuring from earnings, and treats after-tax warranty accruals as a debt-like claim.
Source: Investor Day 2026 (restated for deferred tax asset (DTA) accounting change); Penmark Research estimates.
Source: Investor Day 2026; FY25 Form 10-K; Penmark Research estimates.
| $m (except % & ratios) | FY21A | FY22A | FY23A | FY24A | FY25A | 9M FY26A |
|---|---|---|---|---|---|---|
| Earnings bridge & margin quality | ||||||
| Net sales | 2,773 | 3,756 | 3,954 | 3,866 | 3,768 | 2,884 |
| GAAP net income attributable to Visteon* | 41 | 124 | 568 | 296 | 201 | 85 |
| Provision / (benefit) for income taxes | 31 | 45 | (330) | (8) | 125 | 43 |
| Depreciation and amortisation | 108 | 108 | 104 | 96 | 109 | 89 |
| Non-cash stock-based compensation | 18 | 26 | 34 | 41 | 45 | 35 |
| Restructuring, impairment & net other items | 30 | 45 | 58 | 49 | 12 | 14 |
| Company-defined Adjusted EBITDA | 228 | 348 | 434 | 474 | 492 | 266 |
| Memo: Standardized reported EBITDA (Signals) | n/d | n/d | n/d | 364 | 448 | n/d |
| SBC as % of Adjusted EBITDA | 7.9% | 7.5% | 7.8% | 8.6% | 9.1% | 13.2% |
| Cash conversion & warranty accruals | ||||||
| GAAP operating cash flow / GAAP FCF | 58 / (12) | 167 / 86 | 267 / 142 | 427 / 290 | 410 / 277 | 81 / (22) |
| Adjusted free cash flow (adds restructuring cash) | 22 | 101 | 150 | 300 | 292 | (4) |
| Product warranty & recall accrual (10-Q line, period end) | n/d | n/d | n/d | n/d | 107 | 192 |
*Prior GAAP net income restated for the 2025 DTA method change ($274m pre-restatement for FY24A). Source: FY25 Form 10-K; Q3 FY26 Form 10-Q; Signals; Penmark Research estimates.
Growth split: pass-through vs mix
Annual sales growth swung from over 35% during chip surcharges to slightly negative on routine price-downs. Electric-vehicle delays slowed battery demand in North America and China. Display and controller launches still lifted gross margin over three points since 2019 and helped expand EBITDA margin over five points across several drivers.
Accounting choices & cash conversion
Excluding SBC, netting research and development (R&D) recoveries and accruing warranties shape reported earnings. Non-cash SBC more than doubled to nearly a tenth of adjusted EBITDA, while customer engineering recoveries reduce cost of sales directly. Third-quarter warranty charges and chip buffer stocks pushed nine-month adjusted FCF slightly negative.
Zero-margin surcharges lift next year's sales 14.4% to $4,375m while diluting reported margins
Our ten-year forecast separates core cabin demand from zero-margin memory and circuit-board surcharges. Underlying sales grow as cabin launches more than offset flat car production and our assumed 1.5% annual drag from price-downs and currency. Recovering most of next year's memory bill lifts headline revenue to nearly $4.4bn. Unrecovered chip costs hold next year's adjusted EBITDA near $460m before underlying margins normalise at mid-cycle.
| $m (except % & per-share) | FY25A | FY26E | FY27E | FY28E | FY29E | FY30E | FY35E |
|---|---|---|---|---|---|---|---|
| Revenue equation & component cost recoveries | |||||||
| Growth over Market (ex-output & pricing)* | n/r | n/m | +8.5% | +7.5% | +7.5% | +5.0% | +3.0% |
| Underlying sales (ex-new-wave recoveries)* | 3,768 | 3,717 | 3,933 | 4,206 | 4,498 | 4,699 | 5,360 |
| Component cost inflation ($m / recovery %) | 0 | 124 (86%) | 492 (90%) | 442 (95%) | 405 (100%) | 423 (100%) | 482 (100%) |
| Component cost recoveries in sales | 0 | 107 | 442 | 420 | 405 | 423 | 482 |
| Reported Net sales | 3,768 | 3,824 | 4,375 | 4,626 | 4,903 | 5,122 | 5,842 |
| Reported Net sales growth | −2.5% | +1.5% | +14.4% | +5.7% | +6.0% | +4.5% | +2.5% |
| Margin structure, GAAP EBIT & EPS | |||||||
| Underlying EBITDA (ex-pass-through & warranty) | 492 | 480 | 511 | 559 | 612 | 619 | 590 |
| Underlying EBITDA margin (% underlying sales) | 13.1% | 12.9% | 13.0% | 13.3% | 13.6% | 13.2% | 11.0% |
| Unrecovered chip cost & Q3 warranty charges | 0 | (94) | (49) | (22) | 0 | 0 | 0 |
| Company-defined Adjusted EBITDA | 492 | 386 | 462 | 537 | 612 | 619 | 590 |
| Reported Adjusted EBITDA margin | 13.1% | 10.1% | 10.6% | 11.6% | 12.5% | 12.1% | 10.1% |
| GAAP operating income (after D&A, SBC, restr.) | 321 | 188 | 268 | 340 | 407 | 370 | 304 |
| GAAP Diluted EPS / Adjusted EPS ($)** | 7.28 / 7.74 | 5.07 / 5.93 | 7.73 / 8.04 | 10.58 / 10.74 | 14.11 / 14.30 | 14.58 / 16.34 | n/m** |
*Assumes customer output of −1.0% in FY27E and +1.0% thereafter, plus −1.5% annual net pricing and FX; FY26E −$94m combines −$17.4m chip leakage and −$77.0m warranty charges. **FY35E per-share omitted due to mechanical $125m net-cash buyback sweep. Source: Penmark Research estimates.
| Metric & period | Guide / Plan* | Consensus | Penmark | Gap & analytical driver |
|---|---|---|---|---|
| FY26E Net sales ($m) | 3,800–3,850 | 3,826 | 3,824 | −0.1% vs Street; inside guide (9M $2,884m + Q4 ~$940m) |
| FY26E Adjusted EBITDA ($m) | 370–410 | 401.7 | 386.0 | −3.9% vs Street; inside Oct reset ($77m warranty, 86% recov.) |
| FY26E Adjusted FCF ($m) | 90–130 | n/d | 100.3 | Inside guide; $150m capex & +$59.4m Q4 NWC release |
| FY27E Net sales ($m) | 4,150 (plan) | 4,273 | 4,375.3 | +2.4% vs Street / +5.4% vs plan; $442.4m chip pass-through |
| FY27E Adjusted EBITDA ($m) | 520 (plan) | 494.8 | 462.1 | −6.6% vs Street / −11.1% vs plan; $49.2m unrecovered cost |
| FY27E Diluted EPS ($) | n/d | 9.57 | 7.73 | −19.2% vs Street (Adj. $8.04); lower EBITDA & tax/D&A/sh. |
| FY26E–29E Cum. Adj. FCF ($m) | ~1,000 (plan) | n/d | 776.4 | −22.4% vs plan; lower EBITDA, $77m warranty cash & NWC |
*FY26E shows 22 Oct 2026 formal guidance; FY27E–29E plan shows 25 Jun 2026 Investor Day objectives; consensus per MarketScreener (23 Oct 2026).
Three-year operating cash flow of $1,142m funds $617m of share buybacks after working-capital drags
Cash conversion dips through next year on surcharge receivables and warranty payouts before rebounding from 2028. Working capital tied up in pass-through billings and cash warranty settlements hold next year's FCF near $100m. Annual FCF then rebounds above $250m from 2028, sweeping surplus cash above a $125m net-cash floor into buybacks.
Source: Penmark Research estimates (cash incl. $2m restricted).
Source: Penmark Research estimates (other inputs at base).
Fixed vs variable cost structure
Chips, screens and circuit boards make roughly 85% of cost of sales variable, while R&D and overhead stay largely fixed. Reusing about three-quarters of CDC software alongside a best-cost footprint lowered engineering and overhead costs. Overhead fell two points of sales and gross margin rose over three points since 2019, before underlying margins normalise to 11% at mid-cycle.
Working capital, warranty & capex
Surcharge receivables and warranty payouts weigh on cash before normalising in 2028. Next year absorbs roughly $73m of working capital on pass-through billings alongside $50m of cash warranty settlements. Capital expenditure stays disciplined near 3.5% of sales throughout our forecast.
Balance sheet & buyback mechanics
Our $125m minimum net-cash floor sweeps surplus cash into share repurchases. Steady cash generation funds over $600m of buybacks across 2027 to 2029, retiring roughly a quarter of diluted shares under existing board authorisation. Visteon simultaneously pays down $15m of debt a year and grows its dividend 4% annually.
EPS gap vs Street & driver sensitivities
Our forecast of $7.73 in 2027 GAAP EPS sits $1.84 below published consensus. Lower EBITDA explains nearly $1 of that gap after tax, while unpublished Street tax, D&A and share-count assumptions explain the rest. Every five-point swing in next year's cost recovery shifts EBITDA by about $25m and DCF value by nearly $0.90 per share.
Mid-cycle valuation of $80.23 and DCF of $88.15 bracket our target price
We value Visteon primarily on peer-median enterprise value to trailing EBITDA applied to normalised mid-cycle earnings, cross-checked by a ten-year DCF. Applying an 11% mid-cycle margin to trailing underlying sales avoids capitalising peak launch margins or one-year chip leakage. Deducting trailing SBC and normal restructuring aligns Visteon with our five-peer US supplier median, excluding peers distorted by impairments, spin-offs or International Financial Reporting Standards (IFRS) differences. Full-cycle DCF sits nearly 10% higher because it captures strong launch cash flows over the next five years before margins fade.
| Primary mid-cycle valuation build | Value | 30 Sep 2026 bridge & trading multiples | Value |
|---|---|---|---|
| LTM underlying sales (to 30 Sep 2026, $m) | 3,724.9 | Cash & equivalents ($464m) less debt (−$330m) | +134.0 |
| Mid-cycle underlying EBITDA margin (%) | 11.0% | Non-controlling interests (higher of multiple / JV cash) | (90.0) |
| Mid-cycle underlying EBITDA ($m) | 409.7 | Employee benefit obligations (−$76m) + affiliates (+$29m) | (47.0) |
| Less: LTM SBC (−$46.0m) & normal restr. (−$31.2m) | (77.2) | Accrued Q3 warranty liability, after 25% tax ($77m × 0.75) | (57.8) |
| Normalized EBITDA, reported basis ($m) | 332.6 | Net claims in EV-to-equity bridge ($m) | (60.8) |
| Target peer-median EV / LTM EBITDA (x) | 6.29x | EV / normalized EBITDA at $82.27 price | at $83.87 target | 6.44x | 6.56x |
| Enterprise value ($2,090.5m) + net claims (−$60.8m) | 2,029.8 | EV / FY27E Adj. EBITDA at $82.27 price | 4.6x |
| Primary base value / share (25.3m diluted sh.) | $80.23 | FY27E GAAP P/E at $82.27 price | at $83.87 target | 10.6x | 10.8x |
Source: Q3 FY26 Form 10-Q; Signals peer metrics; Penmark Research estimates.
Source: Penmark Research estimates (30 Sep 2026 balance sheet).
Source: Penmark Research estimates.
Source: Penmark Research estimates (Ke = cost of equity); Street targets per MarketBeat and MarketScreener.
Rolling our $77.14 weighted value forward yields our $83.87 target and Hold call
Our ten-year DCF values Visteon at about $88 per share by discounting future cash flows to present value (PV). WACC is the blended annual return that debt and equity investors require to fund the business, estimated near 9.8% on a 1.30 published beta. Terminal growth is the steady annual rate at which cash flows grow forever after our explicit ten-year forecast, set at 2.5%.
| $m (except per-share & factors) | 4Q26E | FY27E | FY28E | FY29E | FY30E | FY32E | FY35E | Terminal |
|---|---|---|---|---|---|---|---|---|
| Adj. EBITDA excl. specific warranty | 120.0 | 462.1 | 537.3 | 611.8 | 618.7 | 612.7 | 589.6 | n/a |
| Less: SBC, restructuring & D&A | (51.6) | (194.5) | (197.0) | (204.9) | (248.8) | (263.7) | (285.4) | n/a |
| EBIT / NOPAT (after 28% tax) | 68 / 49 | 268 / 193 | 340 / 245 | 407 / 293 | 370 / 266 | 349 / 251 | 304 / 219 | 224.5* |
| Plus D&A, less capex & Δ trade NWC | +44.2 | (100.9) | (38.3) | (54.4) | (46.6) | (39.9) | (41.3) | (46.8)* |
| Unlevered free cash flow | 93.5 | 91.8 | 206.7 | 238.5 | 219.7 | 211.4 | 177.7 | 177.7 |
| Present value at 9.78% WACC | 92.4 | 85.6 | 175.6 | 184.5 | 154.8 | 123.6 | 78.6 | 1,030.7 |
| DCF equity bridge & per-share value | Explicit PV $1,233.2m + terminal PV $1,030.7m = EV $2,263.9m − claims $60.8m = $2,203.2m ($87.08 → $88.15 at 13 Nov) | |||||||
*Terminal column shows FY36E net operating profit after tax (NOPAT) of $224.5m less 20.8% reinvestment at 12.0% return on new invested capital (RONIC), discounted 9.25 years. WACC blends 10.61% Ke (5.10% risk-free rate, 4.24% equity risk premium, 1.30 beta) and 4.50% after-tax debt cost. Source: Penmark Research estimates.
Source: Penmark Research estimates.
Source: Penmark Research estimates.
| Scenario & weight* | Key operating assumptions | Margin / Mult. | FY27E EBITDA | Primary PV | DCF PV | 12m target | Return / Call |
|---|---|---|---|---|---|---|---|
| Bear case (25%) | 75% recov. (90% end); −4% out; +$20m warr. | 10.3% / 4.84x | $284.6m | $49.08 | $53.05 | $53.35 | −35.1% (Sell) |
| Base case (55%) | 90% recov. (100% end); −1% out; +8.5% GoM | 11.0% / 6.29x | $462.1m | $80.23 | $88.15 | $87.22 | +6.0% (Hold) |
| Bull case (20%) | 98% recov. (100% end); +1% out; +9.5% GoM | 12.0% / 7.26x | $532.5m | $103.74 | $105.69 | $112.78 | +37.1% (Buy) |
| Weighted target | PV $77.14 × (1 + 10.61% Ke − 1.90% yield) | 6.56x norm. | n/a | $77.14 | $82.88 | $83.87 | +1.9% (Hold) |
| Robustness flips (2 of 6) | Ke −1pt (7.03x justified mult.) → $93.61 (+13.8%, Buy); Beta 1.10 → $91.96 (+11.8%, Buy); Ke +1pt → $76.16 (−7.4%, Hold) | ||||||
*Scenario probabilities are subjective analyst weights rather than statistical frequencies. Rating follows 12-month price return to our target (+1.9%, inside the −10% to +10% Hold band), excluding dividend yield (+3.8% total return). Source: Penmark Research estimates.
February 2027 guidance tests our Hold call as margin swings reach +$9.25 per share
Seven dated company and industry milestones over the next fifteen months test each operating driver of our thesis. Crossing into Buy requires catalysts that lift our target above $90.50, or a share pullback below $76.24 with fundamentals intact. Moving to Sell requires events that cut our target below $74.04, or a share rally above $93.19 without an earnings upgrade.
| Window | Catalyst event | Key driver | Penmark view vs Street / plan | Value stake / trigger |
|---|---|---|---|---|
| 30 Nov 2026 | CFO Rouquet exit; interim CFO Myers assumes role | Warranty & CFO | Clean control handoff; permanent CFO search update without guidance revision | Neutral ($0/sh); governance watch |
| 4Q26–1Q27 | Geely & SAIC China HPC production starts after Chery | Cockpit GoM | Penmark +8.5% FY27E GoM; upside +1pt to +9.5% if domestic OEM mix accelerates | ~$0.92/sh FY27E ($0.68 DCF) |
| Feb 2027* | 4Q26 results, FY26 Form 10-K & initial FY27 guidance | Cost recovery & margin | Penmark $462.1m FY27E EBITDA (90% recov.) vs $494.8m Street & $520m plan; $0 extra warranty | +$1.17 to −$2.19/sh (decisive test) |
| Feb 2027* | Full-year FY26 new-business wins disclosure | Cockpit GoM | $3.9bn won in 9M26; delayed DDR5 architecture awards test $6.0bn annual target | +$1.60/sh on +1pt FY28–29 GoM |
| Apr–Jul 2027 | 1Q27 & 2Q27 prints: DRAM/PCB supply & OEM schedules | Customer output | Penmark −1.0% FY27E customer output; H1 schedule cuts to −4.0% vs +1.0% rebound | +$1.84 to −$2.76/sh |
| 2H 2027 | Next-gen DDR5 cockpit sourcing & China Tier-1 bidding | Long-run recovery | Penmark 100% pass-through by FY29E; risk OEMs cap long-run recovery at 90% | −$8.33/sh (<$74.04 = Sell) |
| Feb 2028 | FY27 full-year underlying margin print | Mid-cycle margin | Tests 11.0% mid-cycle margin vs 12.0% structural durability or 10.3% reversion | +$9.25 to −$6.72/sh (>$90.50 = Buy) |
*Exact 4Q26 earnings release date unconfirmed by company; February 2027 timing reflects historical 10-K filing schedule (FY25 10-K filed 19 Feb 2026). Source: Penmark Research estimates.
Source: Penmark Research estimates (single-driver value impacts vs $80.23 primary base value).
What upgrades Visteon to Buy (>$90.50 target)
Near-term cost recovery alone is not enough to upgrade the stock from today's price. Reaching Buy requires structural margin proof or a lower discount rate. Pairing near-full 2027 cost recovery with durable 12% mid-cycle margins would lift our target past $93 into Buy.
What downgrades Visteon to Sell (<$74.04 target)
Permanent carmaker pushback on memory cost resets is the fastest path to Sell. Guiding next year's adjusted EBITDA down near $388m would point to roughly 75% cost recovery. Structural 10% pass-through leakage or margin reversion toward 10% would then push our target below $74 into Sell.
Capped cost recovery (−$8.33) and margin reversion (−$6.72) lead per-share downside risks
Both downside and upside surprises can break our Hold rating because our target sits close to today's share price. Our 25% bear-case weight already pulls weighted present value below our base case. Permanent carmaker resistance to memory surcharges would push our target into Sell, whereas durable 12% mid-cycle margins would lift it into Buy.
| Risk factor | Prob. | Value / sh | Mechanism & filing evidence | Thesis-breaking signpost |
|---|---|---|---|---|
| Capped long-run recovery | 25% | −$8.33 | Chinese Tier-1 bidding & OEM software insourcing cap FY29E+ pass-through at 90% vs 100% | DDR5 contract renewals embedding permanent 10% supplier absorption |
| Mid-cycle margin reversion | 35% | −$6.72 | FY23–25 gains prove cyclical; underlying margin reverts to FY16–25's 10.3% mean | Ex-pass-through EBITDA margin slipping below 12.0% in FY27–28 |
| Memory/PCB halts OEM lines | 35% | −$2.76 | DDR4/high-layer PCB shortages cut FY27E customer output to −4.0% vs −1.0% base | 1H27 customer build schedules falling >3% y/y across major OEMs |
| FY27 surcharge pushback | 30% | −$2.19 | OEMs fund only 75% of FY27E's $491.6m chip/PCB bill ($122.9m leakage vs $49.2m base) | Feb 2027 FY27 Adjusted EBITDA guidance near ~$388m (75% recovery) |
| Extra warranty & CFO exit | 20% | −$0.59 | 10-Q flags up to $20m reasonably possible extra warranty charge; CFO exits 30 Nov | New warranty provision in FY26 10-K or prolonged interim CFO tenure |
| Upside risk vs Hold: 12% margin & 98% recovery | 30% / 35% | +$9.25 / +$1.17 | Platform reuse (~75% of CDC software) holds 12.0% mid-cycle margin while OEMs fund 98% of FY27 inflation | Feb 2027 EBITDA guide ≥$500m & underlying margin holding ≥13.3% |
Source: FY25 Form 10-K; Q3 FY26 Form 10-Q & call; October 2026 Form 8-K; Penmark Research estimates.
Source: Penmark Research estimates ($284.6m bear, $462.1m base, $532.5m bull).
What would end our Hold thesis
Combining capped long-run pass-through with margin reversion would push our target into Sell. Sustaining underlying margins near 13% alongside near-full cost recovery would support a Buy upgrade instead. Governance and product quality affect equity value mainly through warranty containment and tariff exposure.
Contractual & customer concentration exposure
Ford, General Motors and Volkswagen generate nearly half of annual sales under purchase orders without minimum volume guarantees. Carmakers can delay cabin or electric-vehicle programmes or cancel orders for convenience. That contract structure shifts volume and fixed-cost risk onto Visteon.
Key-person, trade & product-quality risk
Finance chief Jerome Rouquet's late-November departure coincides with critical 2027 surcharge talks, with Colleen Myers serving as interim CFO. Cross-border manufacturing across Portugal, China and Mexico exposes margins to tariff shifts. Complex cabin electronics also carry warranty risk, underscored by $77m of third-quarter warranty charges across two distinct matters.
Short interest jumped 52% to 4.07m shares into Visteon's third-quarter reset
Visteon trades roughly $47m a day on Nasdaq with a single class of common shares. Positioning is split ahead of 2027 guidance as short interest climbed above five days to cover by late October. Over half of covering Street analysts still rate the stock Buy despite recent target cuts.
| Holder (Rank 1–6) | 2Q26 sh. | q/q chg.* | Holder (Rank 7–12) | 2Q26 sh. | q/q chg.* |
|---|---|---|---|---|---|
| 1. BlackRock | 3,579,723 | +25,908 | 7. State Street | 1,143,022 | +48,715 |
| 2. Vanguard Group | 2,859,036 | +9,680 | 8. Victory Capital | 808,692 | −309,475 |
| 3. American Century | 2,178,685 | −61,516 | 9. Westwood Holdings | 806,071 | n/r* |
| 4. T. Rowe Price | 1,962,483 | +139,762 | 10. Geode Capital | 785,366 | +22,365 |
| 5. Dimensional Fund | 1,538,502 | +134,807 | 11. Wellington Mgmt. | 772,648 | −146,499 |
| 6. Invesco | 1,143,718 | −141,199 | 12. First Trust | 747,202 | +228,161 |
| 13F note: 313 filers reported 31,814,573 shares at 30 Jun 2026 vs 26,695,429 shares outstanding (23 Jul 2026); precise % ownership is omitted because 13F filings double-report shared-discretion and lent shares. | |||||
*q/q change compares 2Q26 (30 Jun 2026) vs 1Q26 (31 Mar 2026) top-20 13F extracts; n/r indicates holder outside top-20 1Q26 return (do not infer new entry or exit). Source: Signals Form 13F data.
Source: Signals bi-weekly short interest through 30 Oct 2026 (5.4 days to cover vs 2.73 at 30 Jun).
Liquidity, short interest & buyback capacity
Elevated short interest represents more than five days of average daily trading volume, double June's level. Average daily turnover approached $48m over the past three months. Ongoing share repurchases under Visteon's remaining authorisation steadily absorb float ahead of February guidance.
Source: Consensus snapshot per MarketBeat and MarketScreener (15 Nov 2026).
Insider Form 4 activity & proxy stakes
Latest proxy disclosure from April 2026 shows insiders held 2.0% of shares, led by CEO Sachin Lawande at 1.6%. Two executives sold modest share blocks in June under pre-scheduled trading plans. Independent directors received routine annual equity grants the same month.
Street targets & trading technicals
Published Street targets span $95 to $135 around a mean near $112. Several brokers including Barclays, UBS and RBC Capital Markets cut their targets over the past quarter, while short positioning and buyback capacity could amplify event-day moves.
Annual sales climb from $3,768m to $5,842m across our ten-year forecast
| $m (except per-share & ratios) | FY25A | FY26E | FY27E | FY28E | FY29E | FY30E | FY35E |
|---|---|---|---|---|---|---|---|
| Income statement & per-share metrics | |||||||
| Net sales | 3,768 | 3,824 | 4,375 | 4,626 | 4,903 | 5,122 | 5,842 |
| Company-defined Adjusted EBITDA | 492 | 386 | 462 | 537 | 612 | 619 | 590 |
| Adjusted EBITDA margin (%) | 13.1% | 10.1% | 10.6% | 11.6% | 12.5% | 12.1% | 10.1% |
| D&A / SBC / Restructuring & other | (171) | (198) | (194) | (197) | (205) | (249) | (285) |
| Operating income (GAAP EBIT) | 321 | 188 | 268 | 340 | 407 | 370 | 304 |
| Profit before tax / Income tax | 338 / (125) | 202 / (63) | 275 / (77) | 345 / (97) | 412 / (115) | 376 / (105) | 313 / (88) |
| Net income attributable to Visteon | 201 | 133 | 189 | 237 | 283 | 259 | 215 |
| Diluted EPS / Adjusted EPS ($)* | 7.28 / 7.74 | 5.07 / 5.93 | 7.73 / 8.04 | 10.58 / 10.74 | 14.11 / 14.30 | 14.58 / 16.34 | n/m* |
| Shares (m) / dividends per share (DPS) ($)* | 27.6 / 0.55 | 26.2 / 1.50 | 24.4 / 1.56 | 22.4 / 1.62 | 20.1 / 1.69 | 17.7 / 1.75 | n/m* |
| Condensed balance sheet, cash flow & return ratios | |||||||
| Cash & restr. cash / Total debt | 773 / 301 | 549 / 326 | 436 / 311 | 421 / 296 | 406 / 281 | 391 / 266 | 391 / 266 |
| Trade working capital / PP&E & intangibles | 342 / 746 | 356 / 811 | 429 / 839 | 439 / 867 | 466 / 895 | 487 / 920 | 555 / 1,059 |
| Visteon shareholders' equity / Net cash | 1,568 / 472 | 1,464 / 223 | 1,514 / 125 | 1,567 / 125 | 1,619 / 125 | 1,667 / 125 | 1,876 / 125 |
| Operating cash flow / Capex | 410 / (133) | 224 / (150) | 259 / (158) | 413 / (162) | 470 / (167) | 457 / (169) | 450 / (193) |
| GAAP FCF / Adjusted FCF | 277 / 292 | 74 / 100 | 101 / 111 | 251 / 256 | 304 / 309 | 288 / 330 | 257 / 304 |
| Share repurchases ($m) | (57) | (236) | (155) | (205) | (258) | (243) | (227) |
| ROE / ROCE / Net debt to Adj. EBITDA | 12.8 / 19.6 / −1.0x | 9.1 / 10.2 / −0.6x | 12.5 / 13.0 / −0.3x | 15.1 / 16.0 / −0.2x | 17.5 / 18.5 / −0.2x | 15.5 / 16.3 / −0.2x | 11.5 / 11.9 / −0.2x |
*FY35E per-share figures omitted because a mechanical $125m net-cash sweep dominates terminal share count. Source: FY25 Form 10-K; Penmark Research estimates (cash includes $2m restricted cash).
| $m (except % KPIs) | 1Q25A | 2Q25A | 3Q25A | 4Q25A | 1Q26A | 2Q26A | 3Q26A | 4Q26E |
|---|---|---|---|---|---|---|---|---|
| Product-line sales disaggregation (single Electronics reportable segment) | ||||||||
| Instrument clusters | 435 | 451 | 421 | 440 | 475 | 447 | 445 | n/m |
| Information displays | 122 | 126 | 117 | 135 | 148 | 161 | 167 | n/m |
| Audio and infotainment | 125 | 140 | 131 | 112 | 116 | 127 | 122 | n/m |
| Cockpit domain controllers (CDC/HPC) | 117 | 111 | 96 | 104 | 94 | 103 | 104 | n/m |
| Body & electrification / Other (incl. HUD) | 98 / 37 | 102 / 39 | 111 / 41 | 109 / 48 | 76 / 45 | 75 / 47 | 81 / 51 | n/m |
| Total Net sales | 934 | 969 | 917 | 948 | 954 | 960 | 970 | 940 |
| Quarterly profitability & operating KPIs | ||||||||
| Adjusted EBITDA (reported) | 129 | 134 | 119 | 110 | 104 | 116 | 46* | 120 |
| Adjusted EBITDA margin (%) | 13.8% | 13.8% | 13.0% | 11.6% | 10.9% | 12.1% | 4.7%* | 12.8% |
| Growth over Market / Customer output | +10% / n/r | −1% / n/r | −5% / n/r | +7% / n/r | +3% / −4% | +4% / −5% | +10% / −5% | MSD* / ~−6% |
*3Q26A adjusted EBITDA includes $77m of warranty charges ($123m or 12.7% excluding them); 4Q26E growth over market reflects mid-single-digit (MSD) guidance. Source: Company filings; Penmark Research estimates.
Reconciliations bridge GAAP net income to $492m of reported adjusted EBITDA and $462.1m next year
| $m (except per-share $) | FY22A | FY23A | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|---|---|
| GAAP net income to company-defined Adjusted EBITDA & normalized EBITDA | |||||||
| GAAP net income attributable to Visteon* | 124 | 568 | 296 | 201 | 133.1 | 188.8 | 237.2 |
| Net income attributable to NCI / Tax / Net int. | 61 | (304) | 0 | 128 | 66.3 | 88.9 | 113.4 |
| Less: Equity in net income of affiliates | 1 | 10 | 3 | (8) | (11.0) | (10.0) | (10.3) |
| Depreciation and amortisation | 108 | 104 | 96 | 109 | 120.8 | 129.8 | 134.2 |
| Non-cash SBC / Restructuring & other items | 54 | 56 | 79 | 62 | 76.8 | 64.7 | 62.8 |
| Company-defined Adjusted EBITDA | 348 | 434 | 474 | 492 | 386.0 | 462.1 | 537.3 |
| Memo: Standardized reported EBITDA (Signals) | n/d | n/d | 364 | 448 | n/m | n/m | n/m |
| GAAP EPS to Adjusted EPS & GAAP FCF to Adjusted FCF | |||||||
| GAAP Diluted EPS / Adjusted EPS ($) | n/r / n/r | n/r / n/r | 10.61* / n/r | 7.28 / 7.74 | 5.07 / 5.93 | 7.73 / 8.04 | 10.58 / 10.74 |
| GAAP OCF / Less capital expenditure | 167 / (81) | 267 / (125) | 427 / (137) | 410 / (133) | 224 / (150) | 259 / (158) | 413 / (162) |
| GAAP FCF / Plus restr. cash = Adjusted FCF | 86 / 101 | 142 / 150 | 290 / 300 | 277 / 292 | 74 / 100 | 101 / 111 | 251 / 256 |
*Prior GAAP net income restated for the 2025 DTA method change ($9.82 pre-restatement FY24A diluted EPS on $274m net income; $10.61 restated). Source: Company filings; Penmark Research estimates.
Glossary of company & sector terms
CDC and HPC: Cabin computers running multiple operating systems on one chip to combine clusters, infotainment and displays, using Visteon's SmartCore software and CognitoAI voice assistant.
DDR4, DDR5 and PCB pass-through: Industry shift from end-of-life DDR4 memory to costlier DDR5 chips and multi-layer circuit boards, driving nearly $500m of 2027 cost inflation.
Growth over Market and CPV: Organic sales growth excluding currency and pricing minus customer-weighted car production growth, lifted by cabin content rising from $125 up to $1,000.
Ratio definitions & peer set
Underlying vs normalised EBITDA: Underlying EBITDA strips out zero-margin chip recoveries and exceptional warranty charges. Normalised EBITDA deducts trailing SBC and normal ten-year restructuring to match peer GAAP-reported EBITDA.
Returns and EV bridge: ROE divides net income by ending equity, while ROCE divides after-tax EBIT by invested capital. Our EV bridge adds debt, joint-venture minority claims, pensions and after-tax warranty accruals, less cash and affiliate stakes.
Peer set: Gentex, Autoliv, Lear, PHINIA and Adient set our peer-median multiple, while BorgWarner, Aptiv and Magna are excluded on impairments, spin-offs or IFRS differences.
Methodology note & known limits
Business type: Products and units automotive electronics supplier reporting in US dollars on Nasdaq, valued on cyclical mid-cycle earnings. Product and regional maps replace sum-of-the-parts analysis because Visteon reports one Electronics segment, and tax swings rule out P/E as our primary method.
Known limits: Peer multiples use trailing reported EBITDA, and trailing underlying sales deduct our estimated 2026 cost-recovery share. Third-quarter warranty charges are treated as unpaid at September, and our equity risk premium uses Damodaran's May 2026 estimate.
Data sources & cut-off dates
Market and estimate cut-off: Data as of 13 Nov 2026, covering Visteon's closing share price, peer prices, ten-year US Treasury yields and Yahoo Finance return series.
Filings and snapshots: Sources include the FY25 Form 10-K (February 2026), Form DEF 14A proxy statement (April 2026), Investor Day presentation (June 2026) and third-quarter Form 10-Q and call (October 2026). Governance and positioning also use October's Form 8-K, Signals Form 13F and short-interest series, and MarketScreener and MarketBeat consensus snapshots.
Analyst certification and important disclosures
Ratings
Ratings are based on the upside from the share price to our 12-month price target, excluding dividends. The price target is weighted across bull, base and bear scenarios.
| Buy | Upside to price target above +10% |
| Hold | Upside to price target from −10% to +10%, inclusive |
| Sell | Upside to price target below −10% |
We review ratings at each set of results and whenever the facts change materially. A share price can move outside its band before the rating changes, and targets may not be reached.
Analyst certification
The Penmark Research Team certifies that (1) the views in this report accurately reflect its views about the subject company and its securities, and (2) no part of its compensation was, is or will be directly or indirectly related to the specific ratings, price targets or views in this report.
Contact
Penmark Research
Questions about our research:
research@penmarkresearch.com
All our research and coverage:
penmarkresearch.com
Basis of preparation
This report uses information publicly available up to its publication date. Share prices are closing prices on the trading day before the publication date, unless stated otherwise. Forecasts, valuations and price targets are Penmark Research’s own, and forecast periods are marked E. Sources are shown beneath each exhibit.
Valuation and price targets
Price targets are based on the valuation methods set out in each report and are weighted across bull, base and bear scenarios. The main risks to each rating and price target are described in the report. Penmark Research updates its coverage after each set of results but is not obliged to update a report at any other time.
Independence and conflicts of interest
Penmark Research is independent. It does not provide investment banking, brokerage, market-making or asset management services, does not trade securities, and does not accept payment from any company for research coverage. Companies do not see or review Penmark Research reports before publication.
No member of the Penmark Research Team holds a long or short position, directly or through derivatives, in the securities of any company Penmark Research covers.
Regulatory status
Penmark Research publishes general, impersonal investment research on a regular basis. It is not registered as an investment adviser with the US Securities and Exchange Commission or any state securities authority, is not a registered broker-dealer and is not a member of FINRA. Penmark Research does not give advice tailored to any person’s circumstances.
Not investment advice or an offer
This report is for information only. It is not personalised investment advice and is not an offer or solicitation to buy or sell any security or other financial instrument. It does not take into account any reader’s objectives, financial situation or needs. Readers should make their own investment decisions and seek independent professional advice where appropriate.
Forward-looking statements and risk
Forecasts, valuations and price targets are estimates based on assumptions that may prove wrong, and they may not be achieved. Opinions are current as of the publication date and may change without notice. Investing in equities involves risk, including the loss of capital. Share prices can be volatile, and past performance is not a reliable indicator of future results.
Data and sources
Company financials, operating data and filings come from company filings, earnings releases and earnings calls. Market data and any consensus estimates come from third-party sources named beneath the relevant exhibit; consensus figures from aggregators are unofficial. Penmark Research does not use other brokers’ research. Third-party data belong to their providers and may not be extracted from this report.
Accuracy and liability
Information is taken from sources believed to be reliable, but Penmark Research makes no representation or warranty as to its accuracy, completeness or timeliness. To the fullest extent permitted by law, Penmark Research accepts no liability for any loss arising from use of this report. Descriptions of litigation and regulatory matters reflect allegations and public records, not findings, unless stated. If a published report is corrected, the corrected version carries an “Updated” date at penmarkresearch.com.
Distribution and access
Penmark Research reports are available to registered users of penmarkresearch.com. Downloads and programmatic access are governed by the Penmark Research subscription terms. This report is not directed at, or intended for, any person in Singapore or India, and access from those countries is blocked. It is not intended for distribution to, or use by, any person in any jurisdiction where that would be contrary to law or regulation or would subject Penmark Research to registration or licensing requirements there.
Copyright and permitted use
© Penmark Research. All rights reserved. Penmark Research is a trade name of Brightriver Labs. Readers may share a link to this report but may not copy, reproduce, redistribute, sell or use its content, including for text and data mining, without written consent. Contact: research@penmarkresearch.com.